Efficacy: Success with less invasive ventilation

CUROSURF administration facilitates transition from
mechanical ventilation (MV)

The table below details the studies in which CUROSURF was used in conjunction with less invasive ventilation. In each study, the addition of CUROSURF to NCPAP helped a majority of infants stay on less invasive ventilation avoiding the need for reintubation or subsequent MV.1-4

Table of study findings with NCPAP use and CUROSURF administration
The Verder 1994 study at the top of the table compares the success rates of infants receiving CUROSURF + NCPAP vs NCPAP alone. Patients who received CUROSURF in conjunction with NCPAP experienced significantly higher success rates vs NCPAP alone.1

In later studies examining the timing of surfactant administration, a greater number of patients achieved success when CUROSURF was administered early vs late.2,3

*NCPAP = nasal continuous positive airway pressure.
†Success with NCPAP was defined as no further need to reintubate for subsequent MV or surfactant redosing.
‡Late surfactant administration was defined as after FiO2 had risen to 0.57–0.77.2

About the INSURE method: INtubate SURfactant Extubate
The INSURE method of stabilizing infants with RDS involves early surfactant administration followed by rapid extubation to NCPAP. In two recent studies of CUROSURF using the INSURE method, at least 81% of infants were able to successfully avoid subsequent MV and reintubation.3,4

Next: Favorable outcomes

Also take a look at how CUROSURF demonstrates a rapid onset of action and sustained results with fewer doses for fast RDS success.

CUROSURF facilitates efficient administration.
Learn More
Interested in evaluating CUROSURF? Find out how you can smoothly integrate CUROSURF into your NICU by participating in the CUROSURF Experience Program.
Learn More

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Click here for full prescribing information

This site is intended for United States residents only.

References: 1. Verder H, Robertson B, Greisen G, et al; for The Danish-Swedish Multicenter Study Group. N Engl J Med. 1994;331:1051-1055. 2. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6. 3. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:e560-e563. 4. Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. J Perinatol. 2007;27:422-427.